NEWS & VIEWS

Global private equity and venture capital news and research

TPG shifts Aptalis exit strategy to IPO following failed $3bn-plus sale process

24 Oct 2013

pharmaceutical 12_sqTPG Capital-backed drugmaker Aptalis Pharma has reportedly hired underwriters for an IPO of the business after its plans to sell the company for more than $3bn failed.

Goldman Sachs and JP Morgan have been tasked with leading the offering according to Reuters, which cited people familiar with the matter.

The news comes less than three months after it emerged TPG had hired JP Morgan and Evercore Partners to explore the sale of the Canada-based business.

TPG bought the drugmaker for $1.3bn in 2007, when it was known as Axcan Pharma, before merging it with Euran Pharmaceuticals in 2011 and renaming it Aptalis.

The company develops and markets prescription products to treat gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, and cholestaticliver diseases.

It recorded revenues of $615m and EBITDA of $269m for fiscal 2012, according to an earlier Reuters report.

In July it was reported that TPG was nearing a deal to acquire Envision Pharmaceutical Holdings, which has annual revenues of more than $3.5bn.

Envision provides pharmacy benefit management services including network-pharmacy claims processing, mail-order, benefit-design consultation, drug-utilisation review, formulary management, disease management, and drug data analysis services.

Copyright © 2013 AltAssets

FUNDRAISING & INVESTOR RELATIONS


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014